LivingGLP1
Study S000370

The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis - a Single-center Randomized Controlled Study

Included trial: extracted dataClinicalTrials.gov recordStudy Protocol and Statistical Analysis Plan (PDF)

Registration

Registration
NCT02765399
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE4
Masking
SINGLE
Status
COMPLETED
Enrollment
23
Start
2015-02-01
Primary completion
2019-02-28
Lead sponsor
Helsinki University Central Hospital
Conditions
Type 2 Diabetes
Interventions
DRUG:Liraglutide; DRUG:Placebo
Results posted
TRUE
Individual participant data sharing
NO

Registered primary outcomes

  • Change in Liver Fat Content [Baseline and after 16 weeks]
  • Plasma Triglyceride (TG) Area Under Curve (AUC) [Baseline and after 16 weeks]
  • Body Weight [Baseline and after 16 weeks]
  • Change in HbA1c Level [Baseline and after 16 weeks]
  • Change in fP-glucose Level [Baseline and after 16 weeks]
  • Change in Insulin Level [Baseline and after16 weeks]
  • Change in Matsuda Index [Baseline and after 16 weeks]
  • Change in VAT Area [Baseline and after 16 weeks]
  • Change in SAT Area [Baseline and after 16 weeks]
  • Change in ApoCIII Level [Baseline and after 16 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0022963Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes.
Taskinen MR, Diabetes, obesity & metabolism
2021OtherPMID 33502078DOIregistry reference RESULT:33502078
R0022111Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.
Matikainen N, Diabetes, obesity & metabolism
2019Randomized trialPMID 30073766DOIregistry reference RESULT:30073766